Purpose: Due to the lack of systematic data on antibiotic sensitivity, the treatment of the
highly prevalent and pathogenic Helicobacter pylori (H. pylori) infection still poses a …

Gastric cancer ranks as the fifth-leading contributor to global cancer incidence and the fourth-
highest in terms of cancer-related mortality. Helicobacter pylori (H. pylori) infection leads to …

Рассмотрены пути оптимизации антахеликобактерной терапии (АХТ) в контексте
увеличения эффективности и безопасности лечения. Рассмотрены перспективы …

Vonoprazan (VPZ), a new potassium-competitive acid blocker, has been approved and used
for Helicobacter pylori eradication in Japan. To date, many studies, as well as several …

Abstract Background Studies with CYP2C19 slow metabolizers have shown that the
combination of a proton pump inhibitor (PPI) plus amoxicillin (dual therapy) can reliably cure …

There have been hundreds of H. pylori eradication trials and yet doubt remains regarding
the best regimen for any situation. With most regimens, treatment failure is the result of …

A steady decline in the effectiveness of standard eradication therapy (ET) regimens for
Helicobacter pylori infection necessitates a search for ways of their optimization, by …

Abstract Background Management of Helicobacter pylori (H. pylori) infection requires co‐
treatment with proton pump inhibitors (PPIs) and the use of antibiotics to achieve successful …

Pro‐inflammatory cytokines and anti‐inflammatory cytokines are produced in gastric mucosa
from inflammatory cells activated by Helicobacter pylori (H. pylori) infection. Of the …

The rate of eradication of Helicobacter pylori with standard triple therapy using omeprazole,
amoxicillin and clarithromycin (OAC) is unacceptable in populations with high rates of …